LY 3015014

Drug Profile

LY 3015014

Alternative Names: LY3015014

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antihyperlipidaemics; Monoclonal antibodies
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypercholesterolaemia

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 07 Apr 2016 Phase-II development of SC formulation is ongoing
  • 01 Jun 2014 Eli Lilly completes a phase II trial in Hypercholesterolaemia in the US, Canada, Czech Republic, Denmark, Japan, Netherlands, Poland and Puerto Rico (NCT01890967)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top